Clinical Reference Lab to Validate Nuclea's Assays | GenomeWeb

NEW YORK (GenomeWeb) – Nuclea Biotechnologies today said it has inked an agreement with Clinical Reference Laboratory to validate three of Nuclea's tests.

As part of the deal, CRL will initially validate Nuclea's Oncogene Science 159 gene-based prostate cancer monitoring test. Nuclea obtained the test when it acquired Wilex, the wholly owned subsidiary of Wilex AG, in September.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.